Jefferies analyst Ian Hilliker maintained a Buy rating on Eli Lilly & Co (NYSE: LLY) on July 13 and set a price target of $100. The company’s shares closed on Friday at $89.71, close to its 52-week high of $89.87.
According to TipRanks.com, Hilliker is a 2-star analyst with an average return of 2.4% and a 64.3% success rate. Hilliker covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Merck & Company, and Bristol Myers.
Eli Lilly & Co has an analyst consensus of Moderate Buy, with a price target consensus of $92.83, which is a 3.5% upside from current levels. In a report issued on July 9, Cantor Fitzgerald also maintained a Buy rating on the stock with a $100 price target.
.
See today’s analyst top recommended stocks >>
Eli Lilly & Co’s market cap is currently $97.37B and has a P/E ratio of 79.13. The company has a Price to Book ratio of 6.70.
Based on the recent corporate insider activity of 109 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through two segments: Human Pharmaceutical Products and Animal Health.
